ANI Pharmaceuticals (ANIP) 10-Q2012 Q1 Quarterly report

Filed: 8 May 12, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: abuse, acute, al, appeal, Aptar, artificially, Baltimore, bid, caption, chronic, compensatory, conclusion, contractor, cure, decision, delisting, depressed, detail, directly, dismissed, District, duty, employee, enrichment, equitable, expanded, expert, exploration, explore, facilitate, false, fiduciary, filling, grace, half, headcount, high, indirectly, inflating, Jazz, Jerome, Lauria, lawsuit, machine, Maryland, meantime, mentioned, merging, mid, misleading, mismanagement, myeloid, nominal, Northern, ordinary, overwhelming, panel, par, path, placebo, plaintiff, punitive, purported, purpose, ratio, reduction, regain, relief, remuneration, repay, resolution, reverse, Rule, secondary, settlement, shareholder, situated, soliciting, split, Stephen, subsidiary, suit, tender, threatened, unissued, unjust, unspecified, vigorously, voluntarily, Weinstein

Removed: accessed, accounted, adjustable, Aduro, asserted, assessment, assumed, awaiting, bear, Biomedical, BioTech, Book, CEFF, Ceregene, collectively, combination, combined, committed, conduct, conform, deducting, delay, designate, determine, entitled, equally, essential, establish, exceeded, exercisable, facility, fee, funding, immunotherapy, influence, infringe, Institute, institutional, investee, issuable, Kingsbridge, larger, licensor, listed, Listeria, Lm, mailing, manufacturing, member, menopausal, met, method, multiple, occurrence, Orange, payment, PDUFA, permitted, personal, personnel, platform, practicable, preclinical, prescription, presentation, previously, pricing, ranging, ranking, reclassified, recoverable, redeem, regulation, REMOVED, RESERVED, retire, reviewed, schedule, scope, secure, secured, separate, sophisticated, source, SPA, spending, spent, structurally, submission, subordinated, successful, suggest, technological, temporarily, thereunder, unmet, unrealized, unsubordinated, Whitehead

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

ANIP similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION OF CEO PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of BioSante Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the quarter ended March 31, 2012 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Stephen M. Simes, Vice Chairman, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

	/s/ Stephen M. Simes
	Stephen M. Simes
	Vice Chairman, President and Chief Executive Officer
	May 8, 2012